Pain, Satisfaction, Consumer
Conditions
Brief summary
Does the use of lidocaine jelly during Mohs surgery on the nose decrease the total amount of lidocaine used during surgery. Does patient satisfaction improve when lidocaine jelly is used during Mohs surgery of the nose?
Detailed description
Hypothesis: Supplementing lidocaine/epinephrine injections with intralesional lidocaine jelly will decrease the overall quantity of lidocaine/epinephrine injectable used, and will decrease patients' self-reported pain/anxiety associated with needle sticks. Objectives: To assess how using lidocaine jelly in Mohs surgery impacts 1) the overall quantity of lidocaine/epinephrine injectable needed to maintain anesthesia, and 2) patients' pain/anxiety associated with anesthesia injections. Background: Mohs micrographic surgery is a procedure that removes cancerous lesions of the skin in a step-wise fashion. Patients are injected with local analgesia for tumor extirpation. The tumor is removed and the tissue is sent for histopathology while the patient waits. Tissue processing time can take up to 2 hours during which the effects of the local analgesia have waned. Once the tissue has been process and examined, patients are brought back to the surgical suite and either have another section of tissue removed (if the margins were positive) or have the wound reconstructed (if the margins were negative). Lidocaine Hydrochloride (Xylocaine) injection with Epinephrine is the traditionally method used to maintain local anesthesia throughout the procedure. The FDA has declared a shortage of this injectable Lidocaine/Epinephrine, stressing the need for a substitute drug. Additionally, multiple needle sticks can be uncomfortable and anxiety provoking for patients. Needle sticks on hypersensitive areas such as the nose can be particularly painful. Previous research has demonstrated that a different form of anesthetic, a topical lidocaine jelly, is efficient in prolonging anesthesia in Mohs surgery (Robins, 1991). No study has published the impact of supplemental lidocaine jelly use on the overall quantity of injection needed, nor on patient pain/anxiety associated with needle sticks. Methods: We will conduct a prospective, randomized trial of 250 patients receiving Mohs micrographic surgery to lesions on the nose. Annually Mohs micrographic surgery is performed on approximately 900 patients with 30% of these procedures being performed on lesions on the nose. Patients receiving Mohs treatment for lesions on the nose will be randomly assigned to one of two groups: (1) those whose wounds will be dressed with lidocaine jelly (treatment group), and (2) those whose wounds will be dressed with surgical lubricant (control/placebo group). All patients will receive a pre-treatment baseline pain/anxiety survey followed by an initial lidocaine injection. The amount of lidocaine/epinephrine injection each patient receives throughout remaining stages of surgery will be recorded, as per the current workflow. All patients will complete a second pain/anxiety survey immediately after numbing but prior to the first stage of surgery. After the first stage of surgery, either lidocaine jelly or surgical lubricant will be applied to the wound followed by a pressure bandage as per standard practice. Dressing are removed immediately prior to the next stage of surgery. After each subsequent stage of surgery, an identical wound dressing will be placed on the operative site. Immediately prior to each subsequent stage of surgery, we will assess patients' pain sensation, and additional lidocaine/epinephrine will be injected if needed. After the surgical site is re-anesthetized, vital signs will be recorded and the Pain/Anxiety survey administered immediately prior to the first incision of that stage.
Interventions
lidocaine 2% jelly applied during Mohs surgery
surgilube (placebo) applied during Mohs surgery
Sponsors
Study design
Eligibility
Inclusion criteria
Patients having Mohs surgery on the nose who are able to consent to the study \>18 years old
Exclusion criteria
unable to consent for themselves known allergy to lidocaine Mohs surgery in locations other than the nose
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Patient Perception of Pain Score | baseline to stage 1 of Mohs surgery, approximately one hour | The mean change of total pain score of patient perception of pain. As measured by the question Rate the pain of your nose from 0 to 10. 0 being no pain, 10 being the worst pain of your life. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Total Amount of Intervention (Lidocaine or Surgilube) Used | Through completion of Mohs surgery, approximately one day | The mean total amount of intervention used as measured by milligrams (mg) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lidocaine Jelly This group had lidocaine jelly applied during Mohs surgery
Lidocaine jelly: lidocaine 2% jelly applied during Mohs surgery | 118 |
| Surgilube This group had surgilube (placebo) applied during Mohs surgery
Surgilube: surgilube (placebo) applied during Mohs surgery | 115 |
| Total | 233 |
Baseline characteristics
| Characteristic | Lidocaine Jelly | Surgilube | Total |
|---|---|---|---|
| Age, Continuous | 72.2 years STANDARD_DEVIATION 10.46 | 71.7 years STANDARD_DEVIATION 11.38 | 72.0 years STANDARD_DEVIATION 10.9 |
| Race/Ethnicity, Customized Asian/Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Hispanic | 2 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown | 2 Participants | 5 Participants | 7 Participants |
| Race/Ethnicity, Customized White | 113 Participants | 109 Participants | 222 Participants |
| Region of Enrollment United States | 118 participants | 115 participants | 233 participants |
| Sex: Female, Male Female | 44 Participants | 53 Participants | 97 Participants |
| Sex: Female, Male Male | 74 Participants | 62 Participants | 136 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 118 | 0 / 115 |
| other Total, other adverse events | 0 / 118 | 0 / 115 |
| serious Total, serious adverse events | 0 / 118 | 0 / 115 |
Outcome results
Mean Change in Patient Perception of Pain Score
The mean change of total pain score of patient perception of pain. As measured by the question Rate the pain of your nose from 0 to 10. 0 being no pain, 10 being the worst pain of your life.
Time frame: baseline to stage 1 of Mohs surgery, approximately one hour
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Lidocaine Jelly | Mean Change in Patient Perception of Pain Score | 0.5 score on a scale |
| Surgilube | Mean Change in Patient Perception of Pain Score | 0.3 score on a scale |
Mean Total Amount of Intervention (Lidocaine or Surgilube) Used
The mean total amount of intervention used as measured by milligrams (mg)
Time frame: Through completion of Mohs surgery, approximately one day
Population: Data was not collected or analyzed for four subjects in each arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine Jelly | Mean Total Amount of Intervention (Lidocaine or Surgilube) Used | 28.1 mg | Standard Deviation 29 |
| Surgilube | Mean Total Amount of Intervention (Lidocaine or Surgilube) Used | 24.4 mg | Standard Deviation 18.8 |